Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Atux Iskay presents new anticancer compounds

Oct. 13, 2021

Discovery and preclinical characterization of novel TLR3 agonist, TL-532

Oct. 13, 2021

Glycogen phosphorylase identified as a therapeutic target for anaplastic thyroid cancer

Oct. 11, 2021

Filling the glass by emptying cancer cells' plates

Oct. 11, 2021

Mirati Therapeutics describes discovery and activity of GTPase KRAS inhibitor MRTX-1133

Oct. 11, 2021

New HIF-2alpha inhibitors discovered at Arcus Biosciences

Oct. 11, 2021

Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical patent A2A/A2B receptor antagonists

Oct. 11, 2021

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent AKT1/AKT2/AKT3 inhibitors

Oct. 11, 2021

Merck KGaA and Ryvu Therapeutics divulge new ACSS2 inhibitors

Oct. 8, 2021

Evotec presents ISR pathway modulators

Oct. 8, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.